David Aaron Feldman

8183295, May 22, 2012

Aug 8, 2008

12/188604

David L Feldman - Teaneck NJ, US
Randy L Webb - Flemington NJ, US

Novartis Pharmaceuticals Corporation - East Hanover NJ

A61K 31/65
A61K 31/4418
A61K 31/4422
A61K 31/5415

514620, 514356, 5142232

The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.

20050124624, Jun 9, 2005

Mar 14, 2003

10/507642

Richard Gilbert - Victoria, AU
Darren Kelly - Victoria, AU
David Feldman - Teaneck NJ, US

A61K031/549
A61K031/506
A61K031/4178
A61K031/401
A61K031/366

514252180, 514381000, 514423000, 514355000, 514223500, 514460000, 514548000

A PDGF receptor tyrosine kinase inhibitor, especially a 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of angiotensin II-induced diseases and a combination which comprises (a) a PDGF receptor tyrosine kinase inhibitor preferably N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one compound selected from an antihypertensive, an aldosterone antagonist, an aldosterone synthase inhibitor and/or an angiotensin receptor blocker agent and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of hypertension and hypertension-induced diseases.

20050182042, Aug 18, 2005

May 16, 2003

10/514683

David Feldman - Teaneck NJ, US
Randy Webb - Flemington NJ, US

A61K031/554
A61K031/549
A61K031/455

514211070, 514223500, 514355000

The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic and to a method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine fibroids comprising administering a therapeutically effective amount of said pharmaceutical composition to a mammal in need of such treatment.

20050209244, Sep 22, 2005

Feb 27, 2003

10/505398

Margaret Prescott - Millburn NJ, US
David Feldman - Teaneck NJ, US

A61K031/506
A61F002/00

514252180, 424423000

The invention relates to the local administration of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt or crystal form thereof, optionally in conjunction with one or more other active ingredients, and a device adapted for such local administration.

20080085914, Apr 10, 2008

Oct 6, 2005

11/576495

David Louis Feldman - Teaneck NJ, US
Friedrich Cameron Luft - Panketal, DE
Dominik Nicolas Mueller - Berlin, DE
Randy Lee Webb - Flemington NJ, US

A61K 31/40
A61K 31/33
A61K 31/41
A61K 31/44
A61K 31/445
A61P 9/00

514303, 514183, 514319, 514359, 514423

The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with

20080161321, Jul 3, 2008

Mar 16, 2005

10/592973

David Louis Feldman - Teaneck NJ, US
Steven Zelenkofske - Center Valley PA, US
Michaela Dinboeck - Basel, CH
Margaret Forney Prescott - Morris Plains NJ, US

A61K 31/496
A61K 31/165
A61P 3/10
A61P 9/12
A61P 9/00
A61P 3/00

51425218, 514616

The present is directed to a method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, PH, malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI, increase of formation of collagen and other extracellular matrix proteins, restenosis after stenting, PVD including PAD and peripheral venous disorders, CAD, morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), AF, renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, AIN, ATN, acute tubulo-interstitial nephritis, PKD, vascular inflammation, rennin secreting tumors, vasculitides or closure, restenosis of dialysis access grafts comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with another active ingredient.

20080234285, Sep 25, 2008

Jan 21, 2005

10/586013

David Louis Feldman - Teaneck NJ, US

A61K 31/496
A61P 35/04
A61P 19/00
A61P 9/00
A61P 17/00
A61P 3/00

51425218

The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one PDGF receptor tyrosine kinase inhibitor.

20120071470, Mar 22, 2012

Nov 30, 2011

13/307567

David Louis Feldman - Teaneck NJ, US
Randy Lee Webb - Flemington NJ, US

A61K 31/549
A61P 9/12

5142235

The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.